Autolus Therapeutics Presented Clinical Data Updates Saturday At 2023 ASH Meeting
Portfolio Pulse from Charles Gross
Autolus Therapeutics plc (NASDAQ:AUTL) presented clinical data updates at the 2023 ASH Meeting, including positive results from the FELIX Phase Ib/II study of obe-cel in r/r B-ALL, showing prolonged event free survival and low immunotoxicity. Long-term data from ALLCAR19 and FELIX Phase Ib studies indicated durable remissions with obe-cel. The ALLCAR19 extension cohorts showed long-term responses in r/r NHL and r/r CLL with low immunotoxicity. Initial data from the MCARTY Phase I study of AUTO8 in multiple myeloma demonstrated good tolerance and responses in all patients. Autolus will discuss the data at an Analyst/Investor event on December 10, 2023.
December 10, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Autolus Therapeutics presented positive clinical data for obe-cel and AUTO8 at the ASH 2023 meeting, indicating potential for future regulatory approvals and market growth.
The positive clinical data presented by Autolus Therapeutics for its therapies obe-cel and AUTO8 are likely to be viewed favorably by investors, potentially leading to increased investor confidence and a positive short term impact on the stock price. The data suggests progress towards regulatory approvals and commercialization, which are critical milestones for biopharmaceutical companies.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100